Skip to content
Homepage
Blog

Prolotherapy for TMJ: Studies, What to Expect and Cost

Prolotherapy for TMJ is a dextrose injection into or around the jaw joint, offered for jaw pain, clicking, hypermobility and recurrent dislocation. This guide summarises the named studies with their dates and sample sizes, who performs the injection, what a session involves and what it costs.

Explore the clinic directory
Published Updated
In this article

Prolotherapy for TMJ is an injection of concentrated dextrose (a sugar solution), sometimes mixed with a local anaesthetic, into or around the temporomandibular joint, offered for jaw pain, clicking, hypermobility and recurrent dislocation. The published evidence is small: a 2026 scoping review found 13 primary clinical studies in total, reported within-group improvements in pain, mouth opening and dislocation recurrence, and found that superiority over placebo or active comparators was inconsistent.

Key Takeaways

  • The largest controlled study in the search results is a randomized, double-blind trial of 30 patients with reducible disc displacement in both jaw joints (Haggag, Al-Belasy and Said Ahmed, Journal of Cranio-Maxillo-Facial Surgery, 2022). It compared 25% dextrose with saline at two sites per joint, with follow-up to 6 months after the last injection. The dextrose group reported greater improvement in pain and mouth opening; joint sounds did not differ significantly.
  • Recurrent dislocation is a different indication. Zhou, Hu and Ding (British Journal of Oral and Maxillofacial Surgery, 2014) treated 45 patients aged 17 to 59 with lignocaine and 50% dextrose at a single site: 41 of 45 had no further dislocation or subluxation for more than 6 months, 26 of them after one injection.
  • Assiri and colleagues (Medical Science Monitor, May 2025) repeated 50% dextrose injections at 1, 3 and 6 months in patients with TMJ disorder symptoms and report pain falling from the third month. The authors call for larger studies with longer follow-up, and the abstract does not state how many patients took part.
  • Kasprzycka and colleagues (Journal of Clinical Medicine, August 2026) mapped 18 reports covering 13 primary clinical studies, 12 of them on excessive jaw mobility and 1 on disc displacement without reduction. No serious adverse events were reported, and the studies were too varied to pool or to identify a best protocol.
  • Regenerated's prolotherapy guide lists $200 to $600 per session, usually not covered by insurance. Medicare's National Coverage Determination 150.7 (CMS, in effect since 27 September 1999) states that reimbursement for prolotherapy should be denied as not reasonable and necessary.

What prolotherapy for TMJ is

Prolotherapy is short for proliferative therapy. A clinician injects an irritant solution, almost always hypertonic dextrose, into a ligament, a joint space or the tissue around a joint, with the intention of provoking a short, local inflammatory response that leads to new connective tissue. The general mechanism, the solutions and the body of evidence for the spine, knee and elbow are covered in Regenerated's prolotherapy guide. This page stays with the jaw.

The temporomandibular joint (TMJ) is the hinge and sliding joint between the lower jaw and the skull, with a cartilage disc between the two bone surfaces. The 2025 review by Kim, Kim, Yun and Ku (Journal of the Korean Association of Oral and Maxillofacial Surgeons, December 2025) describes TMJ prolotherapy as an intra-articular or periarticular injection of a proliferative agent, most often hypertonic dextrose, and in some studies polydeoxyribonucleotide (PDRN). Across the studies below the dextrose concentration ranges from 5% to 50%, and the injection sites named are the upper joint space, the retrodiscal tissue behind the disc, and the periarticular tissue behind the joint.

Clinicians offer it for several TMJ problems that are not the same condition: pain and clicking from a disc that slips and returns (reducible disc displacement), a jaw that opens too far (hypermobility and subluxation), and a jaw that dislocates repeatedly. The studies treat these separately, and so does this page. For the condition itself, see the temporomandibular joint disorder guide.

What the named studies measured

These are the studies that appear for this search, with what each one actually did, taken from its published abstract.

Haggag, Al-Belasy and Said Ahmed, 2022: the randomized trial

This prospective, randomized, double-blind study (Journal of Cranio-Maxillo-Facial Surgery, 2022) enrolled 30 patients with reducible disc displacement in both jaw joints and divided them into two equal groups. After local anaesthesia, each joint was injected at two sites, one in the upper joint space and one in the retrodiscal tissue, with 25% dextrose in one group and normal saline in the other. Pain, maximal mouth opening between the incisors and joint sounds were recorded before treatment, one week after each injection, and 3 and 6 months after the last injection. The authors report significantly greater improvement in pain and mouth opening, and higher satisfaction, in the dextrose group than in the saline group. Joint sounds improved in both groups without a significant difference within or between them.

Zhou, Hu and Ding, 2014: recurrent dislocation, a different indication

This series (British Journal of Oral and Maxillofacial Surgery, 2014) treated 45 patients aged 17 to 59 with recurrent TMJ dislocation not caused by a nerve condition. The injection combined lignocaine with 50% dextrose at a single site in the posterior periarticular tissue. After more than a year of follow-up the authors report that 41 of 45 patients (91%) had no further dislocation or subluxation for more than 6 months; 26 of those 41 needed one injection, 11 needed two and 4 needed three. The authors report that all patients tolerated the injections well. The outcome here is dislocation episodes, not pain, so this study should not be read as evidence about jaw pain or clicking.

Assiri and colleagues, 2025: repeated injections, no control group

This interventional clinical study (Medical Science Monitor, May 2025) enrolled patients with confirmed TMJ disorder symptoms, who completed a questionnaire on symptom intensity, clicking and joint hypermobility. Mouth opening was measured in millimetres and pain on a visual analogue scale. An oral surgeon performed the prolotherapy with 50% dextrose, repeated at 1, 3 and 6 months. The authors report that pain decreased from the third month to the sixth, that mouth opening changed significantly, and that crepitus and discomfort around the ear were reduced after three months. There was no comparison group, the abstract does not state the number of patients, and the authors say much larger studies with longer follow-up are needed before their results can be supported.

The two reviews

Kasprzycka and colleagues (Journal of Clinical Medicine, August 2026) ran a scoping review of dextrose injections across TMJ mobility disorders, searching the literature to 14 June 2026. They included 18 reports: 14 describing 13 primary clinical studies and 4 systematic reviews. Twelve of the primary studies addressed excessive mobility (hypermobility, subluxation and recurrent dislocation) and one addressed disc displacement without reduction with limited mouth opening. In the hypermobility and dislocation studies, within-group reductions in pain, excessive opening and recurrence were commonly reported, but superiority over placebo or active comparators was inconsistent. In the single disc displacement study, 5% dextrose was associated with improvement in pain, mouth opening and chewing, limited by the small sample. No serious adverse events were reported. The authors conclude that the studies were too different from each other to combine or to identify an optimal protocol, and that indication-specific, adequately powered randomized trials are required.

Kim, Kim, Yun and Ku (Journal of the Korean Association of Oral and Maxillofacial Surgeons, December 2025) summarise the clinical and laboratory literature on TMJ prolotherapy. They describe dextrose as the most studied proliferant, PDRN as an alternative used in some studies, and the clinical data as showing reduced pain and improved maximal mouth opening across chronic and degenerative TMJ cases. They describe reported adverse events as minimal and transient, and they call for further controlled studies of long-term clinical and structural outcomes.

StudyDesignPatientsSolution and siteFollow-upReported outcome
Haggag et al., 2022Randomized, double-blind, saline control30, bilateral reducible disc displacement25% dextrose, upper joint space and retrodiscal tissue6 months after last injectionGreater improvement in pain and mouth opening than saline; joint sounds not significantly different
Zhou et al., 2014Case series45, recurrent dislocation, aged 17 to 59Lignocaine plus 50% dextrose, single posterior periarticular siteMore than 1 year41 of 45 free of dislocation for more than 6 months; 1 to 3 injections
Assiri et al., 2025Single-arm interventionalNot stated in abstract; TMJ disorder symptoms50% dextrose, repeated at 1, 3 and 6 months6 monthsPain lower from month 3; mouth opening changed; larger studies needed
Kasprzycka et al., 2026Scoping review to June 202613 primary studies, 4 systematic reviewsDextrose 5% to 50% across studiesVariedWithin-group gains common; superiority over comparators inconsistent; no serious adverse events; no best protocol identified

How it compares with other jaw injections

Prolotherapy is one of several needle procedures offered for the jaw joint. Arthrocentesis rinses the joint space with fluid through fine needles. Hyaluronic acid, platelet-rich plasma (PRP), corticosteroids and non-steroidal anti-inflammatory drugs are injected into the joint for pain and limited opening, and botulinum toxin is injected into the chewing muscles rather than the joint. A 2026 systematic review and meta-analysis of randomized trials in painful articular TMJ disorders (Dos Santos and colleagues, Oral Diseases, March 2026) pooled seven trials with 6-month follow-up and ranked intra-articular tenoxicam, opioids, hyaluronic acid with PRP, and PRP alone for pain reduction and mouth opening. Prolotherapy was not among the procedures it ranked, which is itself a useful fact: the dextrose studies have not yet been compared head to head with those options in that literature.

Regenerated's TMJ treatment directory describes PRP, prolotherapy, hyaluronic acid and stem cell or other biologic injections for the jaw as investigational, with small trials and mixed results, and used off label in the United States. For how prolotherapy differs from PRP in general, see prolotherapy vs PRP.

Who performs it

The jaw studies come from oral and maxillofacial surgery: the 2022 trial was published in a cranio-maxillofacial surgery journal, the 2014 series in the British oral and maxillofacial surgery journal, and the 2025 study referred its patients to an oral surgeon for the injections. In practice, TMJ prolotherapy is offered by oral and maxillofacial surgeons, dentists with orofacial pain training, and physiatrists and pain physicians who already perform dextrose prolotherapy for the spine and limbs. The TMJ treatment directory lists the clinic types that treat the jaw, from dental and orofacial pain practices to oral surgery offices and regenerative medicine clinics, and the prolotherapy clinic directory lists practices that offer the injection for other joints and may also treat the jaw. Directory listings are not recommendations.

What a session involves

The studies describe the procedure in enough detail to know what to expect, though protocols differ.

  • Anaesthesia. The 2022 trial injected after local anaesthesia; the 2014 series mixed lignocaine into the dextrose solution.
  • Injection sites. One site behind the joint in the 2014 series; two sites per joint, the upper joint space and the retrodiscal tissue, in the 2022 trial. Where both joints are affected, both are injected.
  • Number of visits. One to three injections in the 2014 series, repeats at 1, 3 and 6 months in the 2025 study, and a short course with assessment one week after each injection in the 2022 trial. The 2026 scoping review found no optimal protocol in the literature, so the schedule a clinic proposes is its own.
  • What gets measured. Pain on a numeric or visual analogue scale, maximal mouth opening in millimetres between the incisors, joint sounds, and for dislocation patients the number of further episodes. A clinician should record these before the first injection and at each visit.
  • Side effects as reported. The 2014 series reports that all patients tolerated the injections well. The 2026 scoping review reports no serious adverse events across the studies it mapped. The 2025 review describes reported adverse events as minimal and transient. These are the reports in the literature, not a guarantee for any one patient, and injection-site soreness after a deliberately irritant solution is part of the method.

For the general sequence of a prolotherapy course, the prolotherapy treatment guide describes the typical protocol for other joints.

Cost and coverage

Regenerated's prolotherapy guide lists $200 to $600 per session for prolotherapy in general, usually not covered by insurance. Those are clinic list prices collected for the general guide, not a survey of jaw clinics. The jaw studies ranged from a single injection to repeated injections over six months, so the total depends on the protocol the clinician proposes and on whether one or both joints are treated.

Medicare does not pay for it. The Centers for Medicare & Medicaid Services' National Coverage Determination 150.7, in effect since 27 September 1999, covers prolotherapy, joint sclerotherapy and ligamentous injections with sclerosing agents, and states that reimbursement for these modalities should be denied as not reasonable and necessary because their medical effectiveness has not been verified by scientifically controlled studies. CMS describes this as a national noncoverage policy. Private plans generally follow the same line, so expect to pay out of pocket. Ask for a written, itemised quote per injection visit, and ask whether the consultation, imaging or ultrasound guidance is billed separately.

Questions to ask before booking

  • What solution and concentration will be injected? The studies used dextrose from 5% to 50%, with or without a local anaesthetic.
  • Where will the injections go, and is image guidance used? Upper joint space, retrodiscal tissue or periarticular tissue, as in the studies, and whether ultrasound is used to place the needle.
  • How many visits, over what period? The literature has no agreed protocol, so the clinic should explain the schedule it uses and why.
  • Which outcome will you measure? Mouth opening in millimetres, a pain scale, joint sounds or dislocation episodes, recorded before the first injection and at each follow-up.
  • What is your TMJ caseload? Prolotherapy for the knee or back is not the same procedure as an injection into the jaw joint.
  • What happens if my symptoms get worse? Ask what follow-up is included and who to contact.
  • Can I have a written, itemised quote? Per visit, per joint, with any imaging or guidance fees listed.

Frequently asked questions

Does prolotherapy work for TMJ?

The published studies are few and small. A 2022 randomized, double-blind trial of 30 patients with reducible disc displacement reported greater improvement in pain and mouth opening with 25% dextrose than with saline. A 2026 scoping review of 13 primary studies reported within-group improvements but found superiority over placebo or active comparators inconsistent, and called for adequately powered randomized trials. The evidence describes an investigational injection, not an established treatment.

How many prolotherapy injections does TMJ need?

There is no agreed number. In the 2014 recurrent dislocation series, 26 of 41 patients who responded needed one injection, 11 needed two and 4 needed three. The 2025 study repeated injections at 1, 3 and 6 months, and the 2022 trial gave a short course with assessment a week after each injection. The 2026 scoping review found no optimal protocol in the literature, so ask the clinician to explain the schedule proposed.

Is prolotherapy for TMJ covered by insurance or Medicare?

Usually not. Medicare's National Coverage Determination 150.7, in effect since 27 September 1999, is a national noncoverage policy: it states that reimbursement for prolotherapy should be denied as not reasonable and necessary. Regenerated's prolotherapy guide reports that private insurance usually does not cover it either, with list prices of $200 to $600 per session. Expect to pay out of pocket and ask for an itemised quote before the first visit.

What is injected in TMJ prolotherapy?

Hypertonic dextrose, a concentrated sugar solution, at concentrations from 5% to 50% across the published studies, often mixed with a local anaesthetic such as lignocaine. Some studies summarised in the 2025 review used polydeoxyribonucleotide (PDRN) instead. The solution is injected into the upper joint space, into the retrodiscal tissue behind the disc, or into the periarticular tissue behind the joint, depending on the protocol and the condition being treated.

Who does prolotherapy for the jaw?

The published jaw studies come from oral and maxillofacial surgery, and the 2025 study had an oral surgeon perform the injections. Dentists with orofacial pain training, physiatrists and pain physicians who already perform dextrose prolotherapy for other joints also offer it. Regenerated's TMJ treatment directory and prolotherapy clinic directory list practices by location; confirm the clinician's jaw caseload before booking.

Is TMJ prolotherapy the same as PRP for the jaw?

No. Prolotherapy injects a dextrose solution; PRP injects a concentrate of the patient's own platelets prepared from a blood draw. Both are offered for the jaw joint and both are described by Regenerated's TMJ treatment directory as investigational and used off label in the United States. The 2026 Oral Diseases meta-analysis ranked PRP and hyaluronic acid with PRP among intra-articular options; prolotherapy was not among the procedures it compared.

Sources

  1. Haggag MA, Al-Belasy FA, Said Ahmed WM. Dextrose prolotherapy for pain and dysfunction of the TMJ reducible disc displacement: A randomized, double-blind clinical study. Journal of Cranio-Maxillo-Facial Surgery. 2022. doi:10.1016/j.jcms.2022.02.009. PMID 35501215
  2. Zhou H, Hu K, Ding Y. Modified dextrose prolotherapy for recurrent temporomandibular joint dislocation. British Journal of Oral and Maxillofacial Surgery. 2014. doi:10.1016/j.bjoms.2013.08.018. PMID 24064304
  3. Assiri K, Alqarni A, Almubarak H, et al. Efficacy of Prolotherapy for Temporomandibular Joint Dysfunction: An Interventional Clinical Study. Medical Science Monitor. 14 May 2025. doi:10.12659/MSM.946650. PMID 40364487
  4. Kasprzycka J, Chęciński M, Wilk J, et al. Dextrose Injections Across Temporomandibular Joint Mobility Disorders: A Scoping Review. Journal of Clinical Medicine. 29 August 2026. doi:10.3390/jcm15176708. PMC13566233
  5. Kim Y, Kim MJ, Yun PY, Ku JK. Prolotherapy for temporomandibular joint disorders: an updated comprehensive review. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 1 December 2025. doi:10.5125/jkaoms.2025.51.6.354. PMC12766022
  6. Dos Santos MG, da Rosa WLO, Sbardelotto C, et al. Efficacy and Safety of Intra-Articular Therapies for Temporomandibular Disorders: A Systematic Review and Meta-Analysis. Oral Diseases. 12 March 2026. doi:10.1111/odi.70284. PMC13590907
  7. Centers for Medicare & Medicaid Services. National Coverage Determination 150.7, Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents. Effective 27 September 1999. cms.gov
  8. Regenerated. Prolotherapy: How Regenerative Injection Therapy Works and What the Evidence Shows. regenerated.com/blog/prolotherapy/ (source of the per-session cost range cited above)
  9. Regenerated. TMJ treatment clinic directory. regenerated.com/clinics/t/tmj-treatment (source of the investigational and off-label description of jaw injections)

Find clinics

Explore directory profiles by treatment and location.

Browse clinics

Explore the guides